Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

14.14 -0.18 (-1.26%)
Official Closing Price Updated: 4:10 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,308,379
Open 14.32
Bid (Size) 14.15 (1)
Ask (Size) 14.22 (12)
Prev. Close 14.32
Today's Range 14.05 - 14.35
52wk Range 13.93 - 84.46
Shares Outstanding 166,301,231
Dividend Yield 3.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
From Dr. Reddy's Laboratories, Inc.
Via Business Wire
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year. 
Via Benzinga

Performance

YTD
-80.04%
-80.04%
1 Month
-81.97%
-81.97%
3 Month
-82.84%
-82.84%
6 Month
-80.07%
-80.07%
1 Year
-79.11%
-79.11%

More News

Read More
Dr. Reddy’s Q2 & H1FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
From Dr. Reddy’s Laboratories Inc.
Via Business Wire
Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
Via AB Newswire
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
From Aurigene Oncology Limited
Via Business Wire
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories – Elliott Wave Technical Analysis
Via Talk Markets
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Via Investor's Business Daily
Organon Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
Via Talk Markets
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Q1FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
Via Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
From Aurigene Pharmaceutical Services Ltd.
Via Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
Via Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.